Hutchmed Limited

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: $2.9B

Website

Clinical Trials

: A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: Fruquintinib in Combination with Sintilimab

First Posted Date: 2019-04-04

Last Posted Date: 2024-04-25

Lead Sponsor: Hutchmed

Target Recruit Count: 381

Registration Number: NCT03903705

Locations: 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China

Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas

Phase 1

Active, not recruiting

Conditions: Lymphoma

Interventions: Drug: HMPL-689

First Posted Date: 2018-12-26

Last Posted Date: 2024-02-28

Lead Sponsor: Hutchmed

Target Recruit Count: 53

Registration Number: NCT03786926

Locations: 🇪🇸
Hospital Universitario Virgen del Rocio, Seville, Spain
🇵🇱
Uniwersyteckie Centrum Kliniczne, Gdańsk, Poland
🇪🇸
Hospital Universitario Virgen Macarena, Seville, Spain

and more 24 locations

An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma

Phase 1

Active, not recruiting

Conditions: Non Hodgkin Lymphoma

Interventions: Drug: HMPL-523

First Posted Date: 2018-12-19

Last Posted Date: 2024-02-09

Lead Sponsor: Hutchmed

Target Recruit Count: 140

Registration Number: NCT03779113

Locations: 🇫🇮
Helsingin yliopistollinen keskussairaala, Helsinki, Finland
🇪🇸
Institut Català d'Oncologia, Barcelona, Spain
🇵🇱
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego, Wrocław, Poland

and more 29 locations

A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors, Colorectal, and Breast Cancer

Phase 1

Active, not recruiting

Conditions: Triple Negative Breast Cancer
HER2-negative Breast Cancer
Advanced Solid Tumors
Metastatic Colon Cancer
Metastatic Breast Cancer
Hormone Receptor Positive Breast Carcinoma
Rectal Cancer

Interventions: Drug: Fruquintinib (HMPL-013)

First Posted Date: 2017-08-16

Last Posted Date: 2023-02-10

Lead Sponsor: Hutchmed

Target Recruit Count: 129

Registration Number: NCT03251378

Locations: 🇺🇸
St. Joseph Heritage Healthcare, Santa Rosa, California, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States

and more 6 locations

A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Tumors

Interventions: Drug: surufatinib

First Posted Date: 2015-09-15

Last Posted Date: 2024-07-10

Lead Sponsor: Hutchmed

Target Recruit Count: 130

Registration Number: NCT02549937

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Rocky Mountain Cancer Center, Denver, Colorado, United States
🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States

and more 9 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy